AR068058A1 - Metodo para inhibir la inflamacion y la expresion pre-inflamatoria de citoquina/quimioquina usando un analogo de grelina - Google Patents

Metodo para inhibir la inflamacion y la expresion pre-inflamatoria de citoquina/quimioquina usando un analogo de grelina

Info

Publication number
AR068058A1
AR068058A1 ARP080103484A AR068058A1 AR 068058 A1 AR068058 A1 AR 068058A1 AR P080103484 A ARP080103484 A AR P080103484A AR 068058 A1 AR068058 A1 AR 068058A1
Authority
AR
Argentina
Prior art keywords
human ghrelin
aib2
human
dap3
octanosulfonyl
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Dewitt Culler
Zheng Xin Dong
Rakesh Datta
John E Taylor
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR068058A1 publication Critical patent/AR068058A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)

Abstract

Un método para mejorar la inflamacion, inhibir la expresion de las citoquinas y/o quimioquinas proinflamatorias, y tratar diversas enfermedades y/o condiciones que ocurren simultáneamente con el inicio de la inflamacion, en un sujeto que necesita un tratamiento para dichas condiciones, que comprende administrar análogos de grelina humana nativa seleccionados. Reivindicacion 1: Un método para tratar la inflamacion en un sujeto que lo necesita, caracterizado porque comprende administrarle a dicho sujeto una cantidad eficaz de un análogo de peptidilo de grelina, una prodroga de este o una sal aceptable para el uso farmacéutico de este, donde dicho análogo o dicha prodroga de este se selecciona del grupo que consiste en: (Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib2, A6c5)grelina humana (1-28)-NH2; (A6c5)grelina humana (1-28)-NH2; (Aib2,6)grelina humana (1-28)-NH2; (Aib2, A5c12)grelina humana (1-28)-NH2; (Aib2, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Act6)grelina humana (1-28)-NH2; (Aib2, 3-Pal9)grelina humana (1-28)-NH2; (Aib2, Dmt7)grelina humana (1-28)-NH2; (Aib2, Thz7)grelina humana (1-28)-NH2; (A5c2)grelina humana (1-28)-NH2; (Act2)grelina humana (1-28)-NH2; (Aib2, A5c5)grelina humana (1-28)-NH2, (Aib2, A6c5)grelina humana (1-28)-NH2, (Aib2,5)grelina humana (1-28)-NH2, (Aib2, hLeu5)grelina humana (1-28)-NH2, (Aib2, Cha5)grelina humana (1-28)-NH2; (Aib2,6)grelina humana (1-28)-NH2; (Aib2, Act6)grelina humana (1-28)-NH2; (Aib2, Thr6)grelina humana (1-28)-NH2; (Aib2, Abu6)grelina humana (1-28)-NH2; (Aib2, 4-Hyp7)grelina humana (1-28)-NH2; (Aib2, Thz7)grelina humana (1-28)-NH2; (Aib2, Pip7)grelina humana (1-28)-NH2; (Aib2, Dhp7)grelina humana (1-28)-NH2; (Aib2, Ktp7) grelina humana(1-28)-NH2; (Aib2,8)grelina humana (1-28)-NH2; (Aib2, 2-Pal9)grelina humana (1-28)-NH2; (Aib2, 3-PaI9)greIina humana (1-28)-NH2; (Aib2, 4-Pal9)grelina humana (1-28)-NH2; (Aib2, Taz9)grelina humana (1-28)-NH2; (Aib2, 2-Thi9)grelina humana (1-28)-NH2; Aib2, 2-Fua9)grelina humana (1-28)-NH2; (Aib2, Apc9)grelina humana (1-28)-NH2; (Aib2,9)grelina humana (1-28)-NH2; (Aib2,10)grelina humana (1-28)-NH2; (Aib2, Tic7)grelina humana (1-28)-NH2; (Aib6)grelina humana (1-28)-NH2; (A5c5)grelina humana (1-28)-NH2; (A6c5)grelina humana (1-28)-NH2; (Act6)grelina humana (1-28)-NH2; (3-Pal9)grelina humana (1-28)-NH2; (Dmt7)grelina humana (1-28)-NH2; (Thz7)grelina humana (1-28)-NH2; (Aib5)grelina humana (1-28)-NH2; (hLeu5)grelina humana (1-28)-NH2; (Cha5)grelina humana (1-28)-NH2; (Tbr6)grelina humana (1-28)-NH2; (Abu6)grelina humana (1-28)-NH2; (4-Hyp7)grelina humana (1-28)-NH2; (Pip7)grelina. humana (1-28)-NH2; (Dhp7)grelina humana (1-28)-NH2: (Ktp7)grelina humana (1-28)-NH2; (Aib8)grelina humana (1-28)-NH2; (2-Pal9)grelina humana (1-28)-NH2; (4-Pal9)grelina humana (1-28)-NH2; (Taz9)grelina humana (1-28)-NH2; (2-Thi9)grelina humana (1-28)-NH2; (2-Fua9)grelina humana (1-28)-NH2; (Apc9)grelina humana (1-28)-NH2; (Aib9)grelina humana (1-28)-NH2; (Aib10)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), A6c5)grelina humana (1-28)-NH2; (Dap3(octanosuIfoniI), A6c5)grelina humana (1-28)-NH2; (Aib2,6, Dap3(octanosulfonil))grelina. humana (1-28)-NH2; (Aib2, Dap3(octanosuIfoniI), A5c12)greIina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Act6)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), 3-Pal9)grelina humana (1-28)-NH2; (Aib2 Dap3(octanosulfonil), Dmt7)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Thz7)grelina humana (1-28)-NH2; (A5c2, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Act2, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), A5c5)grelina humana (1-28)-NH2; (Aib2,5, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil),hLeu5)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Cha5)grelina humana (1-28)-NH2; (Aib2,6, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfoniI), Thr6)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Abu6)greIina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil),4-Hyp7)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil) Pip7)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Dhp7)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil),Ktp7)grelina humana (1-28)-NH2; (Aib2,8, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib2, .Dap3(octanosulfonil) 2-Pal9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), 3-Pal9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), 4-Pal9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfoniI), Taz9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), 2-Thi9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), 2-Fua9)grelina humana (1-28)-NH2; (Aib2, Dap3(octanosulfonil), Apc9)grelina humana (1-28)-NH2; (Aib29, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Aib210, Dap3(octanosulfonil))grelina humana (1-28)-NH2; (Dap3(octanosulfonil), A6c5)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Aib6)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), .A5c12)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), A5c12, Orn15)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), A5c12, Apc16)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Act6)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 3-PaI9)greIina humana (1-28)-NH2; (Dap3(octanosulfonil), Dmt7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Thz7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil) A5c5)greIina humana (1-28)-NH2; (Dap3(octanosulfonil)Aib5)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), hLeu5)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Cha5)greIina humana (1-28)-NH2; (Dap3(octanosulfonil), Thr6)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Abu6)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 4-Hyp7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Pip7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Dhp7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Ktp7)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Aib8)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 2-Pal9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 3-Pal9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 4-Pal9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Taz9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 2-Thi9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), 2-Fua9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Apc9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Aib9)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), Aib10)grelina humana (1-28)-NH2; (Dap3(octanosulfonil), A5c12, .Orn15)grelina humana (1-28)-NH2; (Dab3(octanosulfonil), A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, A6c5, A5c12, Orn15)grelina humana (1-28)-NH2; (A6c5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2,6, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Act6, A5c12, Orn15)grelina humaba (1-28)-NH2; (Aib2, 3-Pal9, A5c12, Orn15)greIina humana (1-28)-NH2; (Aib2, Dmt7, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Thz7, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, A5c5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2,5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, hLeu5, A5c12, Orn15)grelina. humana (1-28)-NH2; (Aib2, Cha5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2,5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Thr6, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Abu6, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 4-Hyp7, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Pip7, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Dhp7, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Ktp7, A5c12, Orn15)grelina humana (1-28)-NH2; Aib2,8, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 2-Pal9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 3-Pal9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 4,Pal9, A5c12, Orn15)greIina humana (1-28)-NH2; (Aib2, Taz9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 2-Thi9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, 2-Fua9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2, Apc9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2,9, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib2,10, A5c12, Orn15)greIina humana (1-28)-NH2; (Dap3(octanosulfonil), A5c12, Apc16)grelina humana (1-28)-NH2; (Dab3(octanosulfonil), A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, A6c5, A5c12, Apc16)grelina humana (1-28)-NH2; (A6c5, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2,6 A5c12 Apc16)grelina humana (1-28)-NH2; (Aib2, Act6, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, 3-Pal9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Dmt7, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Thz7, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, A5c5,12, Apc16)grelina humana (1-28)-NH2; (Aib2,5, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, hLeu5, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Cha5, A5c12, Apc16)grelina humana (1-28)-NH2; Aib2,6, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Thr6, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Abu6, A5&2, Apc16)grelina humana (1-28)-NH2; (Aib2, 4Hyp7, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Pip7, A5c12, Apc16)grelina humana .(1-28)-NH2; (Aib2, Dhp7, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Ktp7, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2,8, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, 2-Pal9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, 3-Pal9, A5c12, Apc16)greIina humana (1-28)-NH2; (Aib2, 4-Pal9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Taz9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, 2-Thi9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, 2-Fua9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2, Apc9,16, A5c12)grelina humana (1-28)-NH2; (Aib2-9, A5c12, Apc16)grelina humana (1-28)-NH2; (Aib2,10, A5c12, Apc16)grelina humana (1-28)-NH2; (A6c5, A5c12, Orn15)grelina humana (1-28)-NH2; (Aib6, A5c12, Orn15)grelina humana (1-28)-NH2; (Act6, A5c12, Orn15)grelina humana (1-28)-NH2; (3-Pa
ARP080103484 2007-08-08 2008-08-08 Metodo para inhibir la inflamacion y la expresion pre-inflamatoria de citoquina/quimioquina usando un analogo de grelina AR068058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96395107P 2007-08-08 2007-08-08

Publications (1)

Publication Number Publication Date
AR068058A1 true AR068058A1 (es) 2009-11-04

Family

ID=40341953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103484 AR068058A1 (es) 2007-08-08 2008-08-08 Metodo para inhibir la inflamacion y la expresion pre-inflamatoria de citoquina/quimioquina usando un analogo de grelina

Country Status (8)

Country Link
US (5) US8871706B2 (es)
EP (1) EP2185200A4 (es)
JP (3) JP2010535770A (es)
AR (1) AR068058A1 (es)
AU (1) AU2008284269B2 (es)
CA (2) CA2921685A1 (es)
TW (1) TW200916113A (es)
WO (1) WO2009020643A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
PL1937262T3 (pl) 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
EP2547351B1 (en) * 2010-03-15 2016-04-27 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2013163582A1 (en) 2012-04-27 2013-10-31 Cedars-Sinai Medical Center Fungal mycobiome as probiotics, diagnostics and therapeutics
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US20150374718A1 (en) * 2014-06-25 2015-12-31 National Cheng Kung University Zhankuic Acid A and Analogs thereof and Their Use as an Anti-Inflammatory Agent
KR101716806B1 (ko) * 2015-03-20 2017-03-17 서강대학교산학협력단 피부 가려움증의 억제, 개선 또는 완화용 조성물
JP6868854B2 (ja) * 2018-02-19 2021-05-12 独立行政法人国立高等専門学校機構 抗肥満剤及び飲食品組成物の製造方法
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114591871B (zh) * 2022-04-01 2022-09-09 山东省农业科学院 一种短稳杆菌及其酶制剂在畜禽养殖及加工废弃物转化中的应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4003789A (en) 1974-01-30 1977-01-18 Massachusetts Institute Of Technology Triglyceride-accumulating clonal cell line
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
CA2150574A1 (en) 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0783577B1 (en) 1995-07-26 2008-07-09 AstraZeneca AB Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
PL212106B1 (pl) 2002-07-23 2012-08-31 Sod Conseils Rech Applic Analogi greliny, ich zastosowanie oraz sposób identyfikacji związku zdolnego do wiązania się z receptorem GHS
WO2006028429A2 (en) * 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CA2507924A1 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
CA2565324A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US20080269116A1 (en) * 2004-05-11 2008-10-30 Taub Dennis D Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
WO2006045314A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
US20060229250A1 (en) * 2005-03-09 2006-10-12 Jian Zhang Ghrelin associated peptide and its uses
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2007038678A2 (en) * 2005-09-28 2007-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogs of ghrelin
PL1937262T3 (pl) * 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue

Also Published As

Publication number Publication date
JP2010535770A (ja) 2010-11-25
AU2008284269B2 (en) 2012-12-20
CA2695713C (en) 2015-12-08
US20110160133A1 (en) 2011-06-30
US20160206700A1 (en) 2016-07-21
JP2013241445A (ja) 2013-12-05
EP2185200A2 (en) 2010-05-19
US20200360483A1 (en) 2020-11-19
US20150111823A1 (en) 2015-04-23
JP2018138586A (ja) 2018-09-06
WO2009020643A2 (en) 2009-02-12
CA2921685A1 (en) 2009-02-12
US8871706B2 (en) 2014-10-28
TW200916113A (en) 2009-04-16
EP2185200A4 (en) 2013-07-10
AU2008284269A1 (en) 2009-02-12
CA2695713A1 (en) 2009-02-12
WO2009020643A3 (en) 2009-12-30
US20170304403A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
AR068058A1 (es) Metodo para inhibir la inflamacion y la expresion pre-inflamatoria de citoquina/quimioquina usando un analogo de grelina
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
AR110301A1 (es) Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
GT200000184A (es) Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean.
SA519401970B1 (ar) مثبطات حلقية غير متجانسة لناقل مونوكربوكسيلات 4
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
CO2020010193A2 (es) Una composición farmacéutica para la anemia
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CO2019003865A2 (es) Proteína terapéutica
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
CO2020004244A2 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
Ryu et al. Potential beneficial effects of marine peptide on human neuron health
RU2014130894A (ru) Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе

Legal Events

Date Code Title Description
FA Abandonment or withdrawal